Quantum Leap Healthcare Collaborative
search
Agents & Results

Manuscripts

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
I-SPY Trial Manuscript
Close
Close
Close
Close

Featured Publications

New Engl J Med
July 7, 2016
valiparib + carboplatin graduates from I-SPY2

Published Manuscripts

Perlmutter J, Brain S, Brown T, et al.
Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial
.
Med Res Arch
11 (7.2)
:
, 
2023
.
abstract
pdf
doi
Perlmutter J, Brain S, Brown T, et al.
Advocate involvement in Clinical Trials: Lessons from the Patient-centric I-SPY2 Breast Cancer Trial
. In 
 (Eds.), 
Med Res Arch
11 (7.2)
(
); pp.
, 
2023
.
abstract
pdf
link
Boughey JC, Yu H, Dugan CL, et al.
Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial
.
Ann Surg Oncol
(published online)
:
1-10
, 
2023
.
abstract
pdf
doi
Boughey JC, Yu H, Dugan CL, et al.
Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial
. In 
 (Eds.), 
Ann Surg Oncol
(published online)
(
); pp.
1-10
, 
2023
.
abstract
pdf
link
Mukhtar RA, Chau H, Woriax H, et al.
Breast Conservation Surgery and Mastectomy have Similar Locoregional Recurrence Following Neoadjuvant Chemotherapy: Results from 1,462 Patients on the Prospective, Randomized I-SPY2 Trial
.
Ann Surg
(published ahead of print)
:
, 
2023
.
abstract
pdf
doi
Mukhtar RA, Chau H, Woriax H, et al.
Breast Conservation Surgery and Mastectomy have Similar Locoregional Recurrence Following Neoadjuvant Chemotherapy: Results from 1,462 Patients on the Prospective, Randomized I-SPY2 Trial
. In 
 (Eds.), 
Ann Surg
(published ahead of print)
(
); pp.
, 
2023
.
abstract
pdf
link
Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van ‘t Veer L, Sirota M
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
.
Frontiers in Oncol
13
:
1192208
, 
2023
.
abstract
pdf
doi
Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van ‘t Veer L, Sirota M
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
. In 
 (Eds.), 
Frontiers in Oncol
13
(
); pp.
1192208
, 
2023
.
abstract
pdf
link
Magbanua MGM, Brown-Swigart L, Ahmed Z, et al.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
.
Cancer Cell
:
, 
2023
.
abstract
pdf
doi
Magbanua MGM, Brown-Swigart L, Ahmed Z, et al.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
. In 
 (Eds.), 
Cancer Cell
(
); pp.
, 
2023
.
abstract
pdf
link
Parker BA, Shatsky RA, Schwab RB, et al.
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
.
Breast Cancer Res Treat
199
:
281–291
, 
2023
.
abstract
pdf
doi
Parker BA, Shatsky RA, Schwab RB, et al.
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
. In 
 (Eds.), 
Breast Cancer Res Treat
199
(
); pp.
281–291
, 
2023
.
abstract
pdf
link
Chitalia R, Miliotis M, Jahani N, et al.
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
.
Communications Med
3
:
46
, 
2023
.
abstract
pdf
doi
Chitalia R, Miliotis M, Jahani N, et al.
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
. In 
 (Eds.), 
Communications Med
3
(
); pp.
46
, 
2023
.
abstract
pdf
link
Magbanua MGM, van ‘t Veer L, Clark AS, et al.
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study
.
Breast Cancer Res Treat
198
:
383–390
, 
2023
.
abstract
pdf
doi
Magbanua MGM, van ‘t Veer L, Clark AS, et al.
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study
. In 
 (Eds.), 
Breast Cancer Res Treat
198
(
); pp.
383–390
, 
2023
.
abstract
pdf
link
Lang JE, Forero-Torres A, Yee D, et al
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
.
npj Breast Cancer
8
:
128
, 
2022
.
abstract
pdf
doi
Lang JE, Forero-Torres A, Yee D, et al
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
. In 
 (Eds.), 
npj Breast Cancer
8
(
); pp.
128
, 
2022
.
abstract
pdf
link
Li W, Le NN, Onishi N, et al
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
.
Cancers
14
:
4436-4448
, 
2022
.
abstract
pdf
doi
Li W, Le NN, Onishi N, et al
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
. In 
 (Eds.), 
Cancers
14
(
); pp.
4436-4448
, 
2022
.
abstract
pdf
link
Osdoit M, Yau C, Symmans WF, et al.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
.
JAMA Surgery
157
:
1034–1041
, 
2022
.
abstract
pdf
doi
Osdoit M, Yau C, Symmans WF, et al.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
. In 
 (Eds.), 
JAMA Surgery
157
(
); pp.
1034–1041
, 
2022
.
abstract
pdf
link
Chitalia R, Pati S, Bhalerao M, et al.
Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
.
Scientific Data
9
:
440
, 
2022
.
abstract
pdf
doi
Chitalia R, Pati S, Bhalerao M, et al.
Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
. In 
 (Eds.), 
Scientific Data
9
(
); pp.
440
, 
2022
.
abstract
pdf
link
Wolf DM, Yau C, Wulfkuhle JD, et al.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
.
Cancer Cell
40
:
P609-623.E6
, 
2022
.
abstract
pdf
doi
Wolf DM, Yau C, Wulfkuhle JD, et al.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
. In 
 (Eds.), 
Cancer Cell
40
(
); pp.
P609-623.E6
, 
2022
.
abstract
pdf
link
Marczyk M, Mrukwa A, Yau C, et al.
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
.
Annals of Oncology
33
:
814–823
, 
2022
.
abstract
pdf
doi
Marczyk M, Mrukwa A, Yau C, et al.
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
. In 
 (Eds.), 
Annals of Oncology
33
(
); pp.
814–823
, 
2022
.
abstract
pdf
link
Le NN, Li W, Onishi N, et al.
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
.
Tomography
8
:
1208–1220
, 
2022
.
abstract
pdf
doi
Le NN, Li W, Onishi N, et al.
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
. In 
 (Eds.), 
Tomography
8
(
); pp.
1208–1220
, 
2022
.
abstract
pdf
link
Thakran S, Cohen E, Jahani N, et al.
Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
.
Translat Oncol
20
:
101411
, 
2022
.
abstract
pdf
doi
Thakran S, Cohen E, Jahani N, et al.
Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
. In 
 (Eds.), 
Translat Oncol
20
(
); pp.
101411
, 
2022
.
abstract
pdf
link
Nguyen AA-T, Onishi N, Carmona-Bozo J, et al.
Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
.
Tomography
8
:
891–904
, 
2022
.
abstract
pdf
doi
Nguyen AA-T, Onishi N, Carmona-Bozo J, et al.
Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
. In 
 (Eds.), 
Tomography
8
(
); pp.
891–904
, 
2022
.
abstract
pdf
link
Yau C, Osdoit M, van der Noordaa M, et al.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
.
Lancet Oncol
23
:
149-160
, 
2021
.
abstract
pdf
doi
Yau C, Osdoit M, van der Noordaa M, et al.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
. In 
 (Eds.), 
Lancet Oncol
23
(
); pp.
149-160
, 
2021
.
abstract
pdf
link
Clark AS, Yau C, Wolf DM, et al.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
.
Nature Comm
12
:
6428
, 
2021
.
abstract
pdf
doi
Clark AS, Yau C, Wolf DM, et al.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
. In 
 (Eds.), 
Nature Comm
12
(
); pp.
6428
, 
2021
.
abstract
pdf
link
Engebraaten O, Yau C, Berg K, et al.
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
.
Nature Comm
12
:
6427
, 
2021
.
abstract
pdf
doi
Engebraaten O, Yau C, Berg K, et al.
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
. In 
 (Eds.), 
Nature Comm
12
(
); pp.
6427
, 
2021
.
abstract
pdf
link
Yee D, Isaacs C, Wolf D, et al.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
.
Npj Breast Cancer
7
:
131
, 
2021
.
abstract
pdf
doi
Yee D, Isaacs C, Wolf D, et al.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
. In 
 (Eds.), 
Npj Breast Cancer
7
(
); pp.
131
, 
2021
.
abstract
pdf
link
Symmans WF, Yau C, Chen YY, et al.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial
.
JAMA Onc
7
:
1654-1663
, 
2021
.
abstract
pdf
doi
Symmans WF, Yau C, Chen YY, et al.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial
. In 
 (Eds.), 
JAMA Onc
7
(
); pp.
1654-1663
, 
2021
.
abstract
pdf
link
Onishi N, Li W, Newitt DC, et al.
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
.
Radiology
301
:
295–308
, 
2021
.
abstract
pdf
doi
Onishi N, Li W, Newitt DC, et al.
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
. In 
 (Eds.), 
Radiology
301
(
); pp.
295–308
, 
2021
.
abstract
pdf
link
Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
.
Clin Cancer Res
27
:
5299-5306
, 
2021
.
abstract
pdf
doi
Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
. In 
 (Eds.), 
Clin Cancer Res
27
(
); pp.
5299-5306
, 
2021
.
abstract
pdf
link
Pusztai L, Yau C, Wolf DM, et al
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
.
Cancer Cell
39
:
989-998
, 
2021
.
abstract
pdf
doi
Pusztai L, Yau C, Wolf DM, et al
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
. In 
 (Eds.), 
Cancer Cell
39
(
); pp.
989-998
, 
2021
.
abstract
pdf
link
O’Grady N, Gibbs DL, Abdilleh K, et al.
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
.
JAMIA Open
4
:
ooab038
, 
2021
.
abstract
pdf
doi
O’Grady N, Gibbs DL, Abdilleh K, et al.
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
. In 
 (Eds.), 
JAMIA Open
4
(
); pp.
ooab038
, 
2021
.
abstract
pdf
link
Liefaard M, Lips E, Wesseling J, et al
The Way of the Future: Personalizing Treatment Plans Through Technology
.
ASCO EDUCATIONAL BOOK
41
:
12-23
, 
2021
.
abstract
pdf
doi
Liefaard M, Lips E, Wesseling J, et al
The Way of the Future: Personalizing Treatment Plans Through Technology
. In 
 (Eds.), 
ASCO EDUCATIONAL BOOK
41
(
); pp.
12-23
, 
2021
.
abstract
pdf
link
Magbanua MJM, Li W, Wolf DM, et al
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
.
NPJ
7
:
, 
2021
.
abstract
pdf
doi
Magbanua MJM, Li W, Wolf DM, et al
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
. In 
 (Eds.), 
NPJ
7
(
); pp.
, 
2021
.
abstract
pdf
link
Du L, Yau C, Brown-Swigart L, et al
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
.
Annals of Oncology
:
, 
2021
.
abstract
pdf
doi
Du L, Yau C, Brown-Swigart L, et al
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
. In 
 (Eds.), 
Annals of Oncology
(
); pp.
, 
2021
.
abstract
pdf
link
Potter DA, Herrera-Ponzanelli CA, Hinojosa D, et al
Recent advances in neoadjuvant therapy for breast cancer
.
Fac Rev
10
:
, 
2021
.
abstract
pdf
doi
Potter DA, Herrera-Ponzanelli CA, Hinojosa D, et al
Recent advances in neoadjuvant therapy for breast cancer
. In 
 (Eds.), 
Fac Rev
10
(
); pp.
, 
2021
.
abstract
pdf
link
Li W, Newitt DC, Gibbs J, et al.
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
.
npj Breast Cancer
6
:
63
, 
2020
.
abstract
pdf
doi
Li W, Newitt DC, Gibbs J, et al.
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
. In 
 (Eds.), 
npj Breast Cancer
6
(
); pp.
63
, 
2020
.
abstract
pdf
link
Magbanua M, Brown-Swigart L, Wu H, et all
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
.
Ann Oncol
32
:
229-239
, 
2020
.
abstract
pdf
doi
Magbanua M, Brown-Swigart L, Wu H, et all
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
. In 
 (Eds.), 
Ann Oncol
32
(
); pp.
229-239
, 
2020
.
abstract
pdf
link
Basu A, Philip EJ, Dewitt B, et al.
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
.
npj Breast Cancer
6
:
52
, 
2020
.
abstract
pdf
doi
Basu A, Philip EJ, Dewitt B, et al.
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology
. In 
 (Eds.), 
npj Breast Cancer
6
(
); pp.
52
, 
2020
.
abstract
pdf
link
Wolf DM, Yau C, Wulfkuhle J, et al.
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
.
npj Breast Cancer
6
:
48
, 
2020
.
abstract
pdf
doi
Wolf DM, Yau C, Wulfkuhle J, et al.
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
. In 
 (Eds.), 
npj Breast Cancer
6
(
); pp.
48
, 
2020
.
abstract
pdf
link
I-SPY Trial Consortium
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
.
JAMA Oncol
6
:
1355-1362
, 
2020
.
abstract
pdf
doi
I-SPY Trial Consortium
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
. In 
 (Eds.), 
JAMA Oncol
6
(
); pp.
1355-1362
, 
2020
.
abstract
pdf
link
Arasu VA, Kim P, Li W, et al.
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2− Patients
.
J Breast Imaging
2
:
352-360
, 
2020
.
abstract
pdf
doi
Arasu VA, Kim P, Li W, et al.
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2− Patients
. In 
 (Eds.), 
J Breast Imaging
2
(
); pp.
352-360
, 
2020
.
abstract
pdf
link
Tan ET, Wilmes LJ, Joe BN, et al.
Denoising and Multiple Tissue Compartment Visualization of Multi‐b‐Valued Breast Diffusion MRI
.
J Mag Res Imaging
53
:
271–282
, 
2021
.
abstract
pdf
doi
Tan ET, Wilmes LJ, Joe BN, et al.
Denoising and Multiple Tissue Compartment Visualization of Multi‐b‐Valued Breast Diffusion MRI
. In 
 (Eds.), 
J Mag Res Imaging
53
(
); pp.
271–282
, 
2021
.
abstract
pdf
link
Jones EF, Hathi DK, Freimanis R, et al.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
.
Cancers
12
:
1511
, 
2020
.
abstract
pdf
doi
Jones EF, Hathi DK, Freimanis R, et al.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
. In 
 (Eds.), 
Cancers
12
(
); pp.
1511
, 
2020
.
abstract
pdf
link
Li W, Newitt DC, Yun BL, et al.
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
.
Tomogr
6
:
216-222
, 
2020
.
abstract
pdf
doi
Li W, Newitt DC, Yun BL, et al.
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
. In 
 (Eds.), 
Tomogr
6
(
); pp.
216-222
, 
2020
.
abstract
pdf
link
Nguyen AA-T, Arasu VA, Strand F, et al.
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
.
Tomography
6
:
101–110
, 
2020
.
abstract
pdf
doi
Nguyen AA-T, Arasu VA, Strand F, et al.
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
. In 
 (Eds.), 
Tomography
6
(
); pp.
101–110
, 
2020
.
abstract
pdf
link
Onishi N, Li W, Gibbs J, et al.
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
.
Tomography
6
:
77–85
, 
2020
.
abstract
pdf
doi
Onishi N, Li W, Gibbs J, et al.
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
. In 
 (Eds.), 
Tomography
6
(
); pp.
77–85
, 
2020
.
abstract
pdf
link
Malyarenko DI, Newitt DC, Amouzandeh G, et al.
Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
.
Tomography
6
:
86-92
, 
2020
.
abstract
pdf
doi
Malyarenko DI, Newitt DC, Amouzandeh G, et al.
Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
. In 
 (Eds.), 
Tomography
6
(
); pp.
86-92
, 
2020
.
abstract
pdf
link
Nanda R, Liu MC, Yau C, et al.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
.
JAMA Oncol
6
:
676-684
, 
2020
.
abstract
pdf
doi
Nanda R, Liu MC, Yau C, et al.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
. In 
 (Eds.), 
JAMA Oncol
6
(
); pp.
676-684
, 
2020
.
abstract
pdf
link
Chien AJ, Tripathy D, Albain KS, et al.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
.
J Clin Oncol
38
:
1059-1069
, 
2020
.
abstract
pdf
doi
Chien AJ, Tripathy D, Albain KS, et al.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
. In 
 (Eds.), 
J Clin Oncol
38
(
); pp.
1059-1069
, 
2020
.
abstract
pdf
link
Jahani N, Cohen E, Hsieh M-K, et al.
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
.
Scientific Reports
9
:
12114
, 
2019
.
abstract
pdf
doi
Jahani N, Cohen E, Hsieh M-K, et al.
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
. In 
 (Eds.), 
Scientific Reports
9
(
); pp.
12114
, 
2019
.
abstract
pdf
link
Piawah S, Hyland C, Umetsu SE, et al.
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
.
npj Breast Cancer
5
:
17
, 
2019
.
abstract
pdf
doi
Piawah S, Hyland C, Umetsu SE, et al.
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
. In 
 (Eds.), 
npj Breast Cancer
5
(
); pp.
17
, 
2019
.
abstract
pdf
link
Li W, Newitt DC, Wilmes LJ, et al.
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL
.
J Magn Reson Imaging
50
:
1742-1753
, 
2019
.
abstract
pdf
doi
Li W, Newitt DC, Wilmes LJ, et al.
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL
. In 
 (Eds.), 
J Magn Reson Imaging
50
(
); pp.
1742-1753
, 
2019
.
abstract
pdf
link
Partridge SC, Newitt DC, Chenevert TL, et al.
Diffusion-weighted MRI in Multicenter Trials of Breast Cancer
.
Radiol
291
:
546–546
, 
2019
.
abstract
pdf
doi
Partridge SC, Newitt DC, Chenevert TL, et al.
Diffusion-weighted MRI in Multicenter Trials of Breast Cancer
. In 
 (Eds.), 
Radiol
291
(
); pp.
546–546
, 
2019
.
abstract
pdf
link
Esserman L, Hylton N, Asare S, et al.
I-SPY2: Unlocking the Potential of the Platform Trial
.
:
3-22
, 
2018
.
abstract
pdf
doi
Esserman L, Hylton N, Asare S, et al.
I-SPY2: Unlocking the Potential of the Platform Trial
. In 
Z. Antonijevic & R. A. Beckman
 (Eds.), 
Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials
(
Chapman and Hall/CRC
); pp.
3-22
, 
2018
.
abstract
pdf
link
Newitt DC, Zheng Z, Gibbs JE, et al.
Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
.
J Mag Res Imag
49
:
1617-1628
, 
2019
.
abstract
pdf
doi
Newitt DC, Zheng Z, Gibbs JE, et al.
Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
. In 
 (Eds.), 
J Mag Res Imag
49
(
); pp.
1617-1628
, 
2019
.
abstract
pdf
link
Partridge SC, Zhang Z, Newitt DC, et al
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
.
Radiol
289
:
618-627
, 
2018
.
abstract
pdf
doi
Partridge SC, Zhang Z, Newitt DC, et al
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
. In 
 (Eds.), 
Radiol
289
(
); pp.
618-627
, 
2018
.
abstract
pdf
link
Boughey JC, Alvarado MD, Lancaster RB, et al.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
.
npj Breast Cancer
4
:
26
, 
2018
.
abstract
pdf
doi
Boughey JC, Alvarado MD, Lancaster RB, et al.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
. In 
 (Eds.), 
npj Breast Cancer
4
(
); pp.
26
, 
2018
.
abstract
pdf
link
Wulfkuhle JD, Yau C, Wolf DM, et al
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL
.
JCO Precision Oncology
2
:
1-20
, 
2018
.
abstract
pdf
doi
Wulfkuhle JD, Yau C, Wolf DM, et al
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL
. In 
 (Eds.), 
JCO Precision Oncology
2
(
); pp.
1-20
, 
2018
.
abstract
pdf
link
Scheel JR, Kim E, Partridge SC, et al.
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial
.
Am J Roentgenol
210
:
1376-1385
, 
2018
.
abstract
pdf
doi
Scheel JR, Kim E, Partridge SC, et al.
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial
. In 
 (Eds.), 
Am J Roentgenol
210
(
); pp.
1376-1385
, 
2018
.
abstract
pdf
link
Drukker K, Li H, Antropova N, et al.
Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer
.
Cancer Imaging
18
:
12
, 
2018
.
abstract
pdf
doi
Drukker K, Li H, Antropova N, et al.
Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer
. In 
 (Eds.), 
Cancer Imaging
18
(
); pp.
12
, 
2018
.
abstract
pdf
link
Olshen A, Wolf D, Jones EF, et al.
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
.
J Med Imaging
5
:
11014
, 
2018
.
abstract
pdf
doi
Olshen A, Wolf D, Jones EF, et al.
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
. In 
 (Eds.), 
J Med Imaging
5
(
); pp.
11014
, 
2018
.
abstract
pdf
link
Severson TM, Wolf DM, Yau C, et al.
The BRCA1 ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
.
Breast Cancer Res
19
:
99
, 
2017
.
abstract
pdf
doi
Severson TM, Wolf DM, Yau C, et al.
The BRCA1 ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
. In 
 (Eds.), 
Breast Cancer Res
19
(
); pp.
99
, 
2017
.
abstract
pdf
link
Wolf DM, Yau C, Sanil A, et al.
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
.
npj Breast Cancer
3
:
, 
2017
.
abstract
pdf
doi
Wolf DM, Yau C, Sanil A, et al.
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
. In 
 (Eds.), 
npj Breast Cancer
3
(
); pp.
, 
2017
.
abstract
pdf
link
Campbell JI, Yau C, Krass P, et al.
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
.
Breast Cancer Res Treat
165
:
181-191
, 
2017
.
abstract
pdf
doi
Campbell JI, Yau C, Krass P, et al.
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
. In 
 (Eds.), 
Breast Cancer Res Treat
165
(
); pp.
181-191
, 
2017
.
abstract
pdf
link
Vidula N, Yau C, Li J, et al.
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
.
Breast Cancer Res Treat
165
:
129-138
, 
2017
.
abstract
pdf
doi
Vidula N, Yau C, Li J, et al.
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
. In 
 (Eds.), 
Breast Cancer Res Treat
165
(
); pp.
129-138
, 
2017
.
abstract
pdf
link
Jones EF, Ray KM, Li W, et al.
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer
.
Clin Breast Cancer
17
:
e155–e159
, 
2017
.
abstract
pdf
doi
Jones EF, Ray KM, Li W, et al.
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer
. In 
 (Eds.), 
Clin Breast Cancer
17
(
); pp.
e155–e159
, 
2017
.
abstract
pdf
link
Bolan PJ, Kim E, Herman BA, et al.
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial
.
J Mag Res Imaging
46
:
290-302
, 
2017
.
abstract
pdf
doi
Bolan PJ, Kim E, Herman BA, et al.
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial
. In 
 (Eds.), 
J Mag Res Imaging
46
(
); pp.
290-302
, 
2017
.
abstract
pdf
link
Li W, Arasu V, Newitt DC, et al.
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
.
Tomography
2
:
378-387
, 
2016
.
abstract
pdf
doi
Li W, Arasu V, Newitt DC, et al.
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
. In 
 (Eds.), 
Tomography
2
(
); pp.
378-387
, 
2016
.
abstract
pdf
link
Rugo HS, Olopade, OI, DeMichele A, et al.
Adaptive randomization of veliparib-carboplatin treatment in breast cancer
.
New Engl J Med
375
:
23-34
, 
2016
.
abstract
pdf
doi
Rugo HS, Olopade, OI, DeMichele A, et al.
Adaptive randomization of veliparib-carboplatin treatment in breast cancer
. In 
 (Eds.), 
New Engl J Med
375
(
); pp.
23-34
, 
2016
.
abstract
pdf
link
Park JW, Liu MC, Yee D, et al.
Adaptive Randomization of Neratinib in Early Breast Cancer
.
N Engl J Med
375
:
11-22
, 
2016
.
abstract
pdf
doi
Park JW, Liu MC, Yee D, et al.
Adaptive Randomization of Neratinib in Early Breast Cancer
. In 
 (Eds.), 
N Engl J Med
375
(
); pp.
11-22
, 
2016
.
abstract
pdf
link
Magbanua MJM, Wolf DM, Yau C, et al.
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response
.
Breast Cancer Res
17
:
73
, 
2015
.
abstract
pdf
doi
Magbanua MJM, Wolf DM, Yau C, et al.
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response
. In 
 (Eds.), 
Breast Cancer Res
17
(
); pp.
73
, 
2015
.
abstract
pdf
link
Hylton NM, Gatsonis CA, Rosen MA, et al.
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
.
Radiol
279
:
44–55
, 
2016
.
abstract
pdf
doi
Hylton NM, Gatsonis CA, Rosen MA, et al.
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
. In 
 (Eds.), 
Radiol
279
(
); pp.
44–55
, 
2016
.
abstract
pdf
link
DeMichele A, Yee D, Berry D, et al.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
.
Clinical Cancer Research
21
:
2911-2915
, 
2015
.
abstract
pdf
doi
DeMichele A, Yee D, Berry D, et al.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
. In 
 (Eds.), 
Clinical Cancer Research
21
(
); pp.
2911-2915
, 
2015
.
abstract
pdf
link
Price ER, Wong J, Mukhtar R, et al
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer
.
World J Clinical Cases
3
:
607-613
, 
2015
.
abstract
pdf
doi
Price ER, Wong J, Mukhtar R, et al
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer
. In 
 (Eds.), 
World J Clinical Cases
3
(
); pp.
607-613
, 
2015
.
abstract
pdf
link
Clark AS, Chen J, Kapoor S, et al.
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I‐SPY trial (CALGB 150007/150015/ACRIN6657)
.
Cancer Medicine
3
:
693-701
, 
2014
.
abstract
pdf
doi
Clark AS, Chen J, Kapoor S, et al.
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I‐SPY trial (CALGB 150007/150015/ACRIN6657)
. In 
 (Eds.), 
Cancer Medicine
3
(
); pp.
693-701
, 
2014
.
abstract
pdf
link
Newitt DC, Aliu SO, Witcomb N, et al.
Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform
.
Translat Oncol
7
:
94-100
, 
2014
.
abstract
pdf
doi
Newitt DC, Aliu SO, Witcomb N, et al.
Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform
. In 
 (Eds.), 
Translat Oncol
7
(
); pp.
94-100
, 
2014
.
abstract
pdf
link
Cureton EL, Yau C, Alvarado MD, et al.
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
.
Ann Surg Oncol
21
:
2889-2896
, 
2014
.
abstract
pdf
doi
Cureton EL, Yau C, Alvarado MD, et al.
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
. In 
 (Eds.), 
Ann Surg Oncol
21
(
); pp.
2889-2896
, 
2014
.
abstract
pdf
link
Alvarez JV, Pan T-C, Ruth J, et al.
Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy
.
Cancer Cell
24
:
30-44
, 
2013
.
abstract
pdf
doi
Alvarez JV, Pan T-C, Ruth J, et al.
Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy
. In 
 (Eds.), 
Cancer Cell
24
(
); pp.
30-44
, 
2013
.
abstract
pdf
link
Mukhtar RA, Yau C, Rosen M, et al.
Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
.
Ann Surg Oncol
20
:
3823-3830
, 
2013
.
abstract
pdf
doi
Mukhtar RA, Yau C, Rosen M, et al.
Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
. In 
 (Eds.), 
Ann Surg Oncol
20
(
); pp.
3823-3830
, 
2013
.
abstract
pdf
link
DeMichele A, Berry DA, Zujewski J, et al.
Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
.
Clinical Cancer Research
19
:
2817-2823
, 
2013
.
abstract
pdf
doi
DeMichele A, Berry DA, Zujewski J, et al.
Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
. In 
 (Eds.), 
Clinical Cancer Research
19
(
); pp.
2817-2823
, 
2013
.
abstract
pdf
link
Glück S, de Snoo F, Peeters J, et al.
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
.
Breast Cancer Res Treat
139
:
759-767
, 
2013
.
abstract
pdf
doi
Glück S, de Snoo F, Peeters J, et al.
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
. In 
 (Eds.), 
Breast Cancer Res Treat
139
(
); pp.
759-767
, 
2013
.
abstract
pdf
link
Yee D, Haddad T, Albain K, et al.
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development [Correspondence]
.
J. Clin. Oncol.
30
:
Jun-84
, 
2012
.
abstract
pdf
doi
Yee D, Haddad T, Albain K, et al.
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development [Correspondence]
. In 
 (Eds.), 
J. Clin. Oncol.
30
(
); pp.
Jun-84
, 
2012
.
abstract
pdf
link
Esserman LJ, Barker AD, Woodcock J, et al.
A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents
.
Cureus
4
:
e76
, 
2012
.
abstract
pdf
doi
Esserman LJ, Barker AD, Woodcock J, et al.
A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents
. In 
 (Eds.), 
Cureus
4
(
); pp.
e76
, 
2012
.
abstract
pdf
link
Wulfkuhle JD, Berg D, Wolff C, et al.
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
.
Clinical Cancer Research
18
:
6426-6435
, 
2012
.
abstract
pdf
doi
Wulfkuhle JD, Berg D, Wolff C, et al.
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
. In 
 (Eds.), 
Clinical Cancer Research
18
(
); pp.
6426-6435
, 
2012
.
abstract
pdf
link
Esserman LJ, Berry DA, DeMichele A, et al.
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
.
J Clin Oncol
30
:
3242-3249
, 
2012
.
abstract
pdf
doi
Esserman LJ, Berry DA, DeMichele A, et al.
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
. In 
 (Eds.), 
J Clin Oncol
30
(
); pp.
3242-3249
, 
2012
.
abstract
pdf
link
Lips EH, Mukhtar RA, Yau C, et al.
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
.
Breast Cancer Res Treat
136
:
35-43
, 
2012
.
abstract
pdf
doi
Lips EH, Mukhtar RA, Yau C, et al.
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
. In 
 (Eds.), 
Breast Cancer Res Treat
136
(
); pp.
35-43
, 
2012
.
abstract
pdf
link
Hylton NM, Blume JD, Bernreuter WK, et al.
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
.
Radiology
263
:
663-672
, 
2012
.
abstract
pdf
doi
Hylton NM, Blume JD, Bernreuter WK, et al.
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
. In 
 (Eds.), 
Radiology
263
(
); pp.
663-672
, 
2012
.
abstract
pdf
link
Lin C, Buxton MB, Moore D, et al.
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
.
Breast Cancer Res Treat
132
:
871-879
, 
2012
.
abstract
pdf
doi
Lin C, Buxton MB, Moore D, et al.
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
. In 
 (Eds.), 
Breast Cancer Res Treat
132
(
); pp.
871-879
, 
2012
.
abstract
pdf
link
Esserman LJ, Berry DA, Cheang MCU, et al.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
.
Breast Cancer Res Treat
132
:
1049-1062
, 
2012
.
abstract
pdf
doi
Esserman LJ, Berry DA, Cheang MCU, et al.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
. In 
 (Eds.), 
Breast Cancer Res Treat
132
(
); pp.
1049-1062
, 
2012
.
abstract
pdf
link
Esserman LJ, Woodcock J
Accelerating identification and regulatory approval of investigational cancer drugs
.
JAMA
306
:
2608-2609
, 
2011
.
abstract
pdf
doi
Esserman LJ, Woodcock J
Accelerating identification and regulatory approval of investigational cancer drugs
. In 
 (Eds.), 
JAMA
306
(
); pp.
2608-2609
, 
2011
.
abstract
pdf
link
Perlmutter, J
Advocate Involvement in I-SPY 2
.
Breast Disease: A Year Book Quarterly
22
:
21-24
, 
2011
.
abstract
pdf
doi
Perlmutter, J
Advocate Involvement in I-SPY 2
. In 
 (Eds.), 
Breast Disease: A Year Book Quarterly
22
(
); pp.
21-24
, 
2011
.
abstract
pdf
link
Barker AD, Sigman CC, Kelloff GJ, et al.
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
.
Clinical Pharmacol & Therapeutics
86
:
97-100
, 
2009
.
abstract
pdf
doi
Barker AD, Sigman CC, Kelloff GJ, et al.
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
. In 
 (Eds.), 
Clinical Pharmacol & Therapeutics
86
(
); pp.
97-100
, 
2009
.
abstract
pdf
link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative